Abstract Number: 680 • 2014 ACR/ARHP Annual Meeting
Influence of Antimalarial doesn´t Modify the Outcome of Cytopenias in Systemic Lupus Erythematosus
Background/Purpose: To analyze the effect of antimalarials (AM) as preventive factor for the development of severe cytopenias and in their outcome after treatment in a…Abstract Number: 698 • 2014 ACR/ARHP Annual Meeting
Grip Strength Identifies Increased Physical Disability in Women with Systemic Lupus Erythematosus
Background/Purpose: Muscle weakness is common and contributes to physical disability in women with systemic lupus erythematosus (SLE). Recently, the Foundation for the National Institutes of…Abstract Number: 699 • 2014 ACR/ARHP Annual Meeting
Osteonecrosis in Systemic Lupus Erythematosus: Prevalence, Patterns and Outcomes
Background/Purpose: Osteonecrosis is a serious comorbidity of systemic lupus erythematosus (SLE). The reported frequency of symptomatic osteonecrosis in SLE is variable, ranging from 4% to…Abstract Number: 697 • 2014 ACR/ARHP Annual Meeting
Venous and Arterial Thrombosis in SLE: Differences in Natural History
Background/Purpose: Thrombosis is increased in SLE due to disease activity and co-morbid factors including antiphospholipid antibodies. We separately investigated the natural history of venous vs.…Abstract Number: 696 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcome of Intestinal Pseudo-Obstruction in Patients with Systemic Lupus Erythematosus
Background/Purpose: Intestinal pseudo-obstruction (IPO) is a rare clinical syndrome characterized by ineffective intestinal motility. IPO has been recently recognized as an uncommon complication of systemic…Abstract Number: 695 • 2014 ACR/ARHP Annual Meeting
Osteonecrosis in Patients with Systemic Lupus Erythematosus: Risk Factors and Clinical Outcome
Background/Purpose: To study the prevalence of osteonecrosis (ON) in patients with systemic lupus erythematosus (SLE) and to identify the risk factors for development of this…Abstract Number: 694 • 2014 ACR/ARHP Annual Meeting
Lupus Myocarditis: Clinical, Echocardiographic and Magnetic Resonance Characteristics
Background/Purpose Myocarditis is an uncommon manifestation with important morbidity and mortality in patients with Systemic Lupus Erythematosus (SLE). There are scant information about this manifestation…Abstract Number: 693 • 2014 ACR/ARHP Annual Meeting
Acute Myocarditis in Patients with Systemic Lupus Erythematosus: Experience from Affiliated Hospitals of Catholic University of Korea
Background/Purpose: To determine the factors associated with occurrence of acute myocarditis (AMC) and its outcomes in patients with systemic lupus erythematosus (SLE). Methods: This was…Abstract Number: 692 • 2014 ACR/ARHP Annual Meeting
Circulating Anti-Ro/SSA Antibodies Are Associated with the Presence of Severe Mitral Regurgitation in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disorder involving multiple organ systems. The frequency of symptomatic heart disease ranges from 5 to 10%,…Abstract Number: 691 • 2014 ACR/ARHP Annual Meeting
Prevalence of Subclinical Echocardiographic Abnormalities in Patients with Systemic Lupus Erythematosus (SLE)
Background/Purpose: To determine the prevalence of unsuspected echocardiographic abnormalities (excluding pericardial effusion) and to identify associated clinical and laboratory features in a large SLE cohort.…Abstract Number: 689 • 2014 ACR/ARHP Annual Meeting
Prednisone, Disease Activity and Hypertension Independently Predict Cataracts in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Cataract is the most common ocular damage in SLE. It is the second most frequent item in the SLICC/ACR Damage Index. Apart from cumulative…Abstract Number: 690 • 2014 ACR/ARHP Annual Meeting
Lupus Patients Requiring First Corticosteroid Intervention Late in Disease Course – a Phenotypic Description
Background/Purpose The University of Toronto Lupus Clinic (UTLC) recently described the phenotype of a group of inception patients with SLE who remained naïve of corticosteroid…Abstract Number: 688 • 2014 ACR/ARHP Annual Meeting
Corticosteroids in Early Treatment Pathways in SLE
Background/Purpose: The treatment algorithm for patients with new onset systemic lupus erythematosus (SLE) is more variable than that for other rheumatic diseases (e.g. rheumatoid arthritis).…Abstract Number: 687 • 2014 ACR/ARHP Annual Meeting
Effect of Corticosteroid Use By Dose on the Risk of Developing Organ Damage over Time in Systemic Lupus Erythematosus—the Hopkins Lupus Cohort
Background/Purpose: Reduction of corticosteroid dose remains an important goal in the management of systemic lupus erythematosus (SLE). Current standard of care in SLE relies heavily…Abstract Number: 685 • 2014 ACR/ARHP Annual Meeting
Successful Withdrawal and Discontinuation of Immunosuppressants in Lupus Patients: Outcomes and Predictors
Background/Purpose: Physicians and patients (Pts) are hesitant to withdraw immunosuppressant (IS) in Pts in clinical remission as the consequences of this approach are unknown.…
